A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF QPI-1002 FOR PREVENTION OF DELAYED GRAFT FUNCTION IN RECIPIENTS OF A DONATION AFTER BRAIN DEATH OLDER DONOR KIDNEY TRANSPLANT (ReGIFT)